BioSpace News Archive

Business

Catalent Finally Reports Earnings: Despite Losses, Revenue Beat Projections

After multiple delays, the contract manufacturer presents its earnings report for the third quarter of fiscal 2023, bumping its stock by more than 10%.

June 12, 2023
·
2 min read
·
Alejandra Manjarrez
Policy

Chamber of Commerce Seeks to Halt Drug Price Negotiation

In its latest legal challenge to the Inflation Reduction Act, the U.S. Chamber of Commerce has appealed to a federal court to stop drug price negotiations until ongoing litigation plays out.

June 12, 2023
·
5 min read
·
Lisa Munger
Employer Resources

Opinion: Manage a Team? Here’s How to Keep Your Top Performers

Scott Rivers, president and managing partner of an executive search and talent branding firm, weighs in on what managers can do to keep top talent.

June 12, 2023
·
4 min read
·
Scott Rivers
Policy

Pharma Companies, Pharmacies Agree to Pay $19B in Opioid Settlement

More than 3,000 state and local governments will receive nearly $19 billion in payments from drugmakers and pharmacy chains in the most recent round of opioid settlements.

June 12, 2023
·
2 min read
·
Tristan Manalac
Business

Illumina CEO DeSouza Steps Down Amid Activist Attack, Anti-Trust Battle

Francis deSouza resigned from Illumina’s helm after strong campaigning from activist investor Carl Icahn and the ongoing regulatory roadblocks facing the company’s acquisition of GRAIL.

June 12, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Novartis Boosts Kidney Business with $3.2B Chinook Buy

The company is paying $3.2 billion upfront in cash for Chinook’s two immunoglobulin A nephropathy candidates, atrasentan and zigakibart, which will complement its own IgAN hopeful iptacopan.

June 12, 2023
·
2 min read
·
Tristan Manalac
Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness

Beacon Therapeutics Holdings Limited, a leading ophthalmic gene therapy company with a purpose to restore and improve the vision of patients with retinal diseases, launches and will develop a new generation of gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness.

June 12, 2023
·
7 min read
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today provided an update on its ongoing clinical development programs evaluating Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immune-modulator with broad spectrum activity.

June 12, 2023
·
7 min read
BioForest

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

Omeros Corporation announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association Congress in Frankfurt, Germany are now available on Omeros’ website.

June 12, 2023
·
4 min read
Pharm Country

Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy

Neuronetics, Inc. announced that they have received 510 clearance for their obsessive-compulsive disorder Motor Threshold Cap technology for NeuroStar® Advanced Therapy for Mental Health.

June 12, 2023
·
3 min read